Departamento de Genética y Microbiología, Facultad de Biología, Universidad de Murcia, Murcia, Spain.
Microbiol Mol Biol Rev. 2024 Mar 27;88(1):e0018822. doi: 10.1128/mmbr.00188-22. Epub 2024 Mar 6.
SUMMARYThe World Health Organization has established a fungal priority pathogens list that includes species critical or highly important to human health. Among them is the order Mucorales, a fungal group comprising at least 39 species responsible for the life-threatening infection known as mucormycosis. Despite the continuous rise in cases and the poor prognosis due to innate resistance to most antifungal drugs used in the clinic, Mucorales has received limited attention, partly because of the difficulties in performing genetic manipulations. The COVID-19 pandemic has further escalated cases, with some patients experiencing the COVID-19-associated mucormycosis, highlighting the urgent need to increase knowledge about these fungi. This review addresses significant challenges in treating the disease, including delayed and poor diagnosis, the lack of accurate global incidence estimation, and the limited treatment options. Furthermore, it focuses on the most recent discoveries regarding the mechanisms and genes involved in the development of the disease, antifungal resistance, and the host defense response. Substantial advancements have been made in identifying key fungal genes responsible for invasion and tissue damage, host receptors exploited by the fungus to invade tissues, and mechanisms of antifungal resistance. This knowledge is expected to pave the way for the development of new antifungals to combat mucormycosis. In addition, we anticipate significant progress in characterizing Mucorales biology, particularly the mechanisms involved in pathogenesis and antifungal resistance, with the possibilities offered by CRISPR-Cas9 technology for genetic manipulation of the previously intractable Mucorales species.
世界卫生组织已建立真菌优先病原体清单,其中包括对人类健康至关重要或高度重要的物种。在这些病原体中,毛霉目真菌是一个包含至少 39 个种的真菌群,可导致危及生命的感染,即毛霉病。尽管由于对临床使用的大多数抗真菌药物具有固有耐药性,病例不断增加且预后较差,但毛霉目真菌受到的关注有限,部分原因是其遗传操作困难。COVID-19 大流行进一步加剧了病例,一些患者出现了 COVID-19 相关的毛霉病,这突显了增加对这些真菌了解的迫切需要。本文综述了治疗该疾病的重大挑战,包括诊断延迟和不准确、缺乏准确的全球发病率估计以及治疗选择有限。此外,本文还重点介绍了关于疾病发展、抗真菌耐药性和宿主防御反应的机制和基因的最新发现。在鉴定负责侵袭和组织损伤的关键真菌基因、真菌用于侵袭组织的宿主受体以及抗真菌耐药性机制方面已经取得了重大进展。这些知识有望为开发新的抗真菌药物以治疗毛霉病铺平道路。此外,我们预计在毛霉目生物学特性的研究方面将取得重大进展,特别是在发病机制和抗真菌耐药性方面,CRISPR-Cas9 技术为遗传操作以前难以处理的毛霉目物种提供了可能性。